CDC Health Advisory Addresses Limited Availability of Nirsevimab
- Centers for Disease Control and Prevention
- Urgent Care,
- Medical Office,
- Critical Access Hospitals,
- Rural Health Clinics
A new Health Advisory from the Centers for Disease Control and Prevention (CDC) provides options for clinicians to protect infants from respiratory syncytial virus (RSV) in the context of a limited supply of nirsevimab, a long-acting monoclonal antibody immunization product recommended for preventing RSV-associated lower respiratory tract disease in infants.
- In the context of limited supply during the 2023–2024 RSV season, CDC recommends prioritizing available nirsevimab 100mg doses for in…